Organovo Holdings (ONVO) and Galectin Therapeutics (GALT) Financial Contrast
Organovo Holdings (NASDAQ: ONVO) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
This table compares Organovo Holdings and Galectin Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
23.9% of Organovo Holdings shares are owned by institutional investors. Comparatively, 11.2% of Galectin Therapeutics shares are owned by institutional investors. 10.2% of Organovo Holdings shares are owned by insiders. Comparatively, 40.3% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current ratings for Organovo Holdings and Galectin Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Organovo Holdings currently has a consensus price target of $6.94, indicating a potential upside of 308.09%. Galectin Therapeutics has a consensus price target of $3.50, indicating a potential upside of 25.90%. Given Organovo Holdings’ stronger consensus rating and higher probable upside, research analysts plainly believe Organovo Holdings is more favorable than Galectin Therapeutics.
Risk and Volatility
Organovo Holdings has a beta of 3.02, meaning that its stock price is 202% more volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500.
Earnings & Valuation
This table compares Organovo Holdings and Galectin Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Organovo Holdings||$4.33 million||41.66||-$38.77 million||($0.39)||-4.36|
|Galectin Therapeutics||N/A||N/A||-$19.47 million||($0.61)||-4.56|
Galectin Therapeutics has higher revenue, but lower earnings than Organovo Holdings. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Organovo Holdings, indicating that it is currently the more affordable of the two stocks.
Organovo Holdings beats Galectin Therapeutics on 9 of the 12 factors compared between the two stocks.
About Organovo Holdings
Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.